Overview
Compare with NEXGEL, INC., ALLURION TECHNOLOGIES, INC. or WORK Medical Technology Group LTD, or pick any stock.
- TickerPLSM on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersL31
- Incorporated inIsrael2
- Business addressOmarim 8, Omer, Israel, 84965002
- Filer categoryNon-accelerated filer, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
Our ordinary shares have been listed on the Nasdaq since January 21, 2026 under the symbol “PLSM”.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue16¢$2.0M
- Research and development43¢$5.4M
- Other costs23¢$2.9M
- Interest18¢$2.3M
- Income tax0¢$1.0K
Out of $12.5M in revenue.4 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues | 9.5M ILS | 9.7M ILS | 6.2M ILS |
| Revenues from settlement agreement with GEHC (*) | 30.5M ILS | ||
| Total revenues | 40.0M ILS | 9.7M ILS | 6.2M ILS |
| Cost of revenues | 6.3M ILS | 6.1M ILS | 4.0M ILS |
| Gross profit | 33.7M ILS | 3.6M ILS | 2.2M ILS |
| Research and development expenses, net | 17.4M ILS | 20.1M ILS | 31.4M ILS |
| Sales and marketing expenses | 11.8M ILS | 10.3M ILS | 9.4M ILS |
| General and administrative expenses | 16.7M ILS | 15.3M ILS | 17.0M ILS |
| Operating loss | 12.2M ILS | 42.2M ILS | 55.6M ILS |
| Financial expenses | 7.2M ILS | 540.0K ILS | 16.2M ILS |
| Financial income | -3.5M ILS | -6.0M ILS | -13.4M ILS |
| Financial expenses (income), net | 3.7M ILS | -5.4M ILS | 2.9M ILS |
| Loss before income tax | 15.9M ILS | 36.8M ILS | 58.4M ILS |
| Provision (benefit) for income tax | 1.0K ILS | -56.0K ILS | 127.0K ILS |
| Net loss and comprehensive loss | 15.9M ILS | 36.7M ILS | 58.6M ILS |
| Loss per ordinary share - basic | 2.46 ILS | 5.76 ILS | 9.12 ILS |
| Loss per ordinary share - diluted | 2.46 ILS | 5.76 ILS | 9.12 ILS |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 21.6M ILS | 41.2M ILS | 23.9M ILS | 15.4M ILS |
| Short-term bank deposits | 47.5M ILS | 62.9M ILS | ||
| Restricted deposits | 140.0K ILS | 140.0K ILS | ||
| Trade receivables | 4.1M ILS | 3.9M ILS | ||
| Other receivables | 1.4M ILS | 1.2M ILS | ||
| Inventory - current portion | 6.6M ILS | 23.1M ILS | ||
| Total current assets | 81.4M ILS | 132.4M ILS | ||
| Inventory - non-current portion | 13.3M ILS | |||
| Right-of-use assets | 1.3M ILS | 1.8M ILS | 3.0M ILS | |
| Property and equipment, net | 5.8M ILS | 7.6M ILS | 9.0M ILS | |
| Total non-current assets | 20.4M ILS | 9.4M ILS | ||
| Total assets | 101.8M ILS | 141.8M ILS | ||
| Trade payables | 2.0M ILS | 2.4M ILS | ||
| Other payables and accruals | 4.4M ILS | 3.8M ILS | ||
| Contract liabilities | 938.0K ILS | 5.1M ILS | ||
| Share-based compensation liability | 276.0K ILS | 1.5M ILS | ||
| Current maturities of liability for royalties to the Israel Innovation Authority | 1.7M ILS | 532.0K ILS | ||
| Current maturities of lease liabilities | 1.0M ILS | 999.0K ILS | 923.0K ILS | |
| Total current liabilities | 10.3M ILS | 14.3M ILS | ||
| Contract liabilities | 22.9M ILS | |||
| Share-based compensation liability, net of current maturities | 164.0K ILS | |||
| Liability for royalties to the Israel Innovation Authority, net of current maturities | 7.9M ILS | 6.5M ILS | ||
| Lease liabilities, net of current maturities | 542.0K ILS | 1.1M ILS | 2.4M ILS | |
| Total non-current liabilities | 8.4M ILS | 30.7M ILS | ||
| Total liabilities | 18.8M ILS | 44.9M ILS | ||
| Ordinary shares | 2.0K ILS | 2.0K ILS | ||
| Share premium | 256.1M ILS | 253.2M ILS | ||
| Capital reserve | $10.1M | $11.0M | $8.0M | |
| Accumulated deficit | -183.1M ILS | -167.3M ILS | ||
| Total equity | 83.1M ILS | 96.9M ILS | 132.2M ILS | 187.5M ILS |
| Total liabilities and equity | 101.8M ILS | 141.8M ILS |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 21.6M ILS | 41.2M ILS | 23.9M ILS | 15.4M ILS |
| Short-term bank deposits | 47.5M ILS | 62.9M ILS | ||
| Restricted deposits | 140.0K ILS | 140.0K ILS | ||
| Trade receivables | 4.1M ILS | 3.9M ILS | ||
| Other receivables | 1.4M ILS | 1.2M ILS | ||
| Inventory - current portion | 6.6M ILS | 23.1M ILS | ||
| Total current assets | 81.4M ILS | 132.4M ILS | ||
| Inventory - non-current portion | 13.3M ILS | |||
| Right-of-use assets | 1.3M ILS | 1.8M ILS | 3.0M ILS | |
| Property and equipment, net | 5.8M ILS | 7.6M ILS | 9.0M ILS | |
| Total non-current assets | 20.4M ILS | 9.4M ILS | ||
| Total assets | 101.8M ILS | 141.8M ILS | ||
| Trade payables | 2.0M ILS | 2.4M ILS | ||
| Other payables and accruals | 4.4M ILS | 3.8M ILS | ||
| Contract liabilities | 938.0K ILS | 5.1M ILS | ||
| Share-based compensation liability | 276.0K ILS | 1.5M ILS | ||
| Current maturities of liability for royalties to the Israel Innovation Authority | 1.7M ILS | 532.0K ILS | ||
| Current maturities of lease liabilities | 1.0M ILS | 999.0K ILS | 923.0K ILS | |
| Total current liabilities | 10.3M ILS | 14.3M ILS | ||
| Contract liabilities | 22.9M ILS | |||
| Share-based compensation liability, net of current maturities | 164.0K ILS | |||
| Liability for royalties to the Israel Innovation Authority, net of current maturities | 7.9M ILS | 6.5M ILS | ||
| Lease liabilities, net of current maturities | 542.0K ILS | 1.1M ILS | 2.4M ILS | |
| Total non-current liabilities | 8.4M ILS | 30.7M ILS | ||
| Total liabilities | 18.8M ILS | 44.9M ILS | ||
| Ordinary shares | 2.0K ILS | 2.0K ILS | ||
| Share premium | 256.1M ILS | 253.2M ILS | ||
| Capital reserve | $10.1M | $11.0M | $8.0M | |
| Accumulated deficit | -183.1M ILS | -167.3M ILS | ||
| Total equity | 83.1M ILS | 96.9M ILS | 132.2M ILS | 187.5M ILS |
| Total liabilities and equity | 101.8M ILS | 141.8M ILS |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net cash used in operating activities | -32.9M ILS | -41.5M ILS | -49.7M ILS |
| Purchase of property and equipment | -135.0K ILS | -509.0K ILS | -3.9M ILS |
| Proceeds from short-term deposits | 10.6M ILS | 51.4M ILS | 53.8M ILS |
| Interest received | 3.4M ILS | 7.7M ILS | 6.9M ILS |
| Net cash provided by investing activities, net | 13.8M ILS | 58.6M ILS | 56.7M ILS |
| Exercise of options | 25.0K ILS | 3.0K ILS | 2.0K ILS |
| Payment to the Israel Innovation Authority | -397.0K ILS | -108.0K ILS | -297.0K ILS |
| Receipt of grants from Israel Innovation Authority | 1.7M ILS | 492.0K ILS | |
| Principal portion of lease payments | -1.2M ILS | -1.2M ILS | -994.0K ILS |
| Interest portion of lease payments | -165.0K ILS | -292.0K ILS | -347.0K ILS |
| Net cash provided by (used in) financing activities | 4.0K ILS | -1.6M ILS | -1.1M ILS |
| Increase (decrease) in cash and cash equivalents | -19.0M ILS | 15.6M ILS | 5.9M ILS |
| Exchange differences on cash and cash equivalents | -542.0K ILS | 1.7M ILS | 2.6M ILS |
| Net loss | -15.9M ILS | -36.7M ILS | -58.6M ILS |
| Depreciation and amortization | 2.8M ILS | 2.9M ILS | 2.4M ILS |
| Share-based compensation | 667.0K ILS | 1.4M ILS | 3.3M ILS |
| Financial expenses (income) | -1.5M ILS | -4.9M ILS | 9.3M ILS |
| Exchange differences | 5.0M ILS | -552.0K ILS | -6.4M ILS |
| Adjustments for profit loss | 7.0M ILS | -1.2M ILS | 8.5M ILS |
| Decrease (increase) in trade receivables | -235.0K ILS | -2.9M ILS | 9.0M ILS |
| Decrease (increase) in other receivables | -154.0K ILS | 135.0K ILS | 1.5M ILS |
| Decrease (increase) in inventory | 3.2M ILS | 598.0K ILS | -9.4M ILS |
| Decrease in trade payables | -379.0K ILS | -2.6M ILS | -936.0K ILS |
| Increase (decrease) in other payables and accruals | 627.0K ILS | 1.1M ILS | -62.0K ILS |
| Increase (decrease) in contract liabilities | -27.1M ILS | 157.0K ILS | |
| Increase in liability of share-based compensation | 18.0K ILS | 117.0K ILS | 246.0K ILS |
| Changes in operating asset and liability items, net | -24.1M ILS | -3.5M ILS | 392.0K ILS |
| Changes in right-of-use asset and lease liabilities | 473.0K ILS | -244.0K ILS | 119.0K ILS |
No quarter-by-quarter statement was filed.
Corporate structure
Pulsenmore Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Pulsenmore Ltd.
- Aquamarine Financial (Cayman) Ltd Filed SCHEDULE 13G on Pulsenmore Ltd., latest Oct 8, 2026
- Elazar Sonnenschein Filed SCHEDULE 13G on Pulsenmore Ltd., latest Apr 28, 2026
- Pulsenmore Ltd. L3
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Pulsenmore Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, net | $1.8M4 Dec 31, 2025 | ||
| Operating-lease assets (leased space) | $403.0K4 Dec 31, 2025 |
Investments
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $6.2M4 Dec 31, 2025 |
Leadership
Who has led Pulsenmore Ltd., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerElazar Sonnenschein Mar 18, 2026 to now5
- Chief financial officerEran Hirsh Mar 18, 2026 to now6
Board members and other officers (9)
- VP Software DevelopmentMeir Shmouely Mar 18, 2026 to now7
- GC & Corporate SecretaryMichael Hamelsdorf Mar 18, 2026 to now8
- VP R&DMinelu Sonnenschein Mar 18, 2026 to now9
- Board memberAnat Loewenstein Mar 18, 2026 to now10
- Board memberElazar Sonnenschein Mar 18, 2026 to now5
- Board memberHagai Itkin Mar 18, 2026 to now11
- Board memberJonathan Adereth Mar 18, 2026 to now12
- Board memberLinda Messalem Mar 18, 2026 to now13
- Board memberRacheli Guz-Lavi Mar 18, 2026 to now14
Named in SEC Form D filings
People the company listed in its private-offering notices.
- VP R&DMenashe Sonnenschein named Jul 7, 202615
Timeline
- Mar 18, 2026New chief executive Elazar Sonnenschein becomes CEO5
Filings
50 filings to the SEC since October 2021: 1 annual reports, 12 insider forms, 2 large holders, 1 private raises, 34 other. The latest 20:
- Oct 14, 20264 EDGAR
- Oct 14, 20263 EDGAR
- Oct 13, 20266-K EDGAR
- Oct 8, 2026SCHEDULE 13G EDGAR
- Sep 17, 20266-K EDGAR
- Sep 8, 20266-K EDGAR
- Sep 1, 2026EFFECT EDGAR
- Aug 31, 2026POS AM EDGAR
- Aug 31, 2026S-8 EDGAR
- Aug 31, 20266-K EDGAR
- Aug 19, 20266-K EDGAR
- Aug 17, 20266-K EDGAR
- Aug 6, 20266-K EDGAR
- Jul 13, 2026424B3 EDGAR
- Jul 13, 20266-K EDGAR
- Jul 10, 2026EFFECT EDGAR
- Jul 7, 2026D EDGAR
- Jul 2, 2026F-1 EDGAR
- Jul 1, 20266-K EDGAR
- Jul 1, 20266-K EDGAR
The 50 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Aquamarine Financial (Cayman) LtdSCHEDULE 13G, 1 filing Oct 8, 202616
- Elazar SonnenscheinSCHEDULE 13G, 1 filing Apr 28, 202617
Money raised
Private offerings the company reported to the SEC on Form D.
- Jun 26, 2026Raised $7.5 million in a private offering of securities Form D: 1 investor so far Form D
SEC filer profile
How Pulsenmore Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARPulsenmore Ltd.1
- CIK0002064764
- Filer statusNon-accelerated filer an emerging growth company; a shell company3
- Incorporated inIsrael3
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business addressOmarim 8, Omer, Israel, Israel 8496500, Israel1
- Phone972 52 606 20751
- Shares outstanding6,502,844 shares as of Mar 15, 20263
- AuditorKesselman & Kesselman, Tel-Aviv, Israel PCAOB ID 1309; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceMay 12, 20251
- Filings50 in all: 6-K (20), 3 (11), DRS/A (4), EFFECT (2), SCHEDULE 13G (2), 20-F (1), 20FR12B (1), 4 (1)1
All 16 form types
424B3 (1), CERT (1), D (1), DRS (1), F-1 (1), POS AM (1), S-8 (1), SEC STAFF ACTION (1)
- Latest filingsAnnual report (20-F) Mar 30, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary shares, par value NIS 0.00032 per share | PLSM | Nasdaq |
From the cover page of the 20-F filed Mar 30, 2026 (Section 12(b) of the Exchange Act).3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARPulsenmore Ltd. filings on SEC EDGAR
- 2SEC EDGARPulsenmore Ltd. filings on SEC EDGAR
- 3
- 4SEC EDGARPulsenmore Ltd. 10-K for fiscal 2025
- 5
- 6SEC EDGAREran Hirsh, Chief financial officer
- 7
- 8
- 9SEC EDGARMinelu Sonnenschein, VP R&D
- 10SEC EDGARAnat Loewenstein, Board member
- 11SEC EDGARHagai Itkin, Board member
- 12SEC EDGARJonathan Adereth, Board member
- 13SEC EDGARLinda Messalem, Board member
- 14SEC EDGARRacheli Guz-Lavi, Board member
- 15
- 16
- 17